The JAK1/JAK2 inhibitor momelotinib, currently under investigation for patients with MF and anemia, has potent inhibitory activity against ACVR1/ALK2 and may become a second-line treatment option for patients who have to eventually stop ruxolitinib due to excessive anemia [30, 31]. The gene discussed is ACVR1; the disease is anemia (phenotype).